Biotech, Cannabis, Food & Drug, & Pharma Law Updates

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotech, Cannabis, Food & Drug, & Pharma Administration News

Title
Publication Date Organization
Feb
28
2023
FDA Asked to Allow “Healthy” Claims on Coffee Keller and Heckman LLP
Feb
28
2023
China Announces Draft Standard on Nutritional Fortification Substances: What Will its Impact Be on Alternative Protein Foods? Keller and Heckman LLP
Feb
28
2023
Will the U.S. Supreme Court Make Marijuana Legal? Bradley Arant Boult Cummings LLP
Feb
28
2023
This Week in 340B: February 21 – 27, 2023 McDermott Will & Emery
Feb
27
2023
Old North State Report – Feb. 27, 2023 Nelson Mullins
Feb
27
2023
FDA Publishes List of 2023 Priority Guidance Topics Keller and Heckman LLP
Feb
27
2023
DEA Announces Permanent Flexibilities for the Prescribing of Controlled Substances via Telemedicine Polsinelli PC
Feb
27
2023
DEA’s Proposed Rules on Telemedicine Controlled Substances Prescribing after the PHE Ends Foley & Lardner LLP
Feb
25
2023
No Surprises Act Update: Certified IDR Entities to Resume Payment Determinations for Services Furnished Before October 25, 2022 Sheppard, Mullin, Richter & Hampton LLP
Feb
25
2023
HHS-OIG Declines to Impose Sanctions on Drug Manufacturer for Financial Assistance to Pediatric Patients with Rare Disease Barnes & Thornburg LLP
Feb
24
2023
Cosmetics – Moving From Voluntary Compliance to Mandatory Regulation Beveridge & Diamond PC
Feb
24
2023
From the Year of the Tiger to the Year of the Rabbit Keller and Heckman LLP
Feb
24
2023
FDA Files Civil Money Penalty Complaints Against Four Small Vape Shops for Alleged Premarket Review Violations Keller and Heckman LLP
Feb
24
2023
Tenth Circuit Declares No Remedy for Hemp Farmer Whose Federally Legal Plants Were Seized ArentFox Schiff LLP
Feb
24
2023
FDA Releases Draft Guidance on Labeling of Plant-Based Milk Alternatives Keller and Heckman LLP
Feb
23
2023
Coverage for Rotten Eggs: Livestock Coverage in the Event of a Crisis Hunton Andrews Kurth
Feb
23
2023
Modified REMS, Clarification on Mailing Drugs, and Movement in Texas Case Mark Significant Weeks in the Reproductive Health Legal Sphere ArentFox Schiff LLP
Feb
23
2023
THC-Oh No! The DEA Classifies Delta-8 and Delta-9 THCO as Controlled Substances
Feb
23
2023
Walking the Highwire of Affiliate Marketing and Advertising Claims [PODCAST] Greenberg Traurig, LLP
Feb
22
2023
CMS Releases Guidance on Implementation of Rebate Programs for Certain Medicare Part B and Part D Drugs Sheppard, Mullin, Richter & Hampton LLP
Feb
21
2023
Lawsuit Alleges PFAS in Pomegranate Juice Keller and Heckman LLP
Feb
21
2023
The 2023 Farm Bill and the Future of Hemp Bradley Arant Boult Cummings LLP
Feb
20
2023
Old North State Report – Feb. 20, 2023 Nelson Mullins
Feb
18
2023
EPA Announces Both EPA and FDA Seek Public Input on Modernizing Their Approach to Oversight of Certain Products Bergeson & Campbell, P.C.
Feb
17
2023
Delta-What??!!- Delta-8 and Delta-9 Create High Anxiety for Policymakers Norris McLaughlin P.A.
Feb
17
2023
Bankruptcy Court Dismisses Cannabis Company Employee’s Chapter 13 Case Squire Patton Boggs (US) LLP
Feb
17
2023
FDA Sued for Denying Petition Related to Antibiotic Use Keller and Heckman LLP
Feb
16
2023
FDA Issues Guidance on Protein Quality Studies for Infant Formula Keller and Heckman LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins